Literature DB >> 9815779

Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells.

A Ogata1, D Chauhan, M Urashima, G Teoh, S P Treon, K C Anderson.   

Abstract

Interleukin 6 (IL-6) is a growth factor for multiple myeloma (MM) cells, yet not all MM cell lines or patient cells require IL-6 for their growth. It is well known that IL-6 activates the signal transducers and activators of transcription (stat) 1-stat3 heterodimer, stat3 homodimer, and Ras-dependent mitogen-activated protein kinase (MAPK) cascades in multiple cell systems. We have shown previously that the MAPK pathway is an important pathway for IL-6-mediated MM cell growth. In this study, we delineate the pattern of upstream MAPK cascade activation in IL-6-responsive B9 cells and in IL-6-nonresponsive U266, OCI-My5, and RPMI8226 MM cells to define sites of blockade of this pathway associated with loss of responsiveness to IL-6. In B9 cells, IL-6 triggered the following in sequence: gp130 phosphorylation, gp130-to-protein tyrosine phosphatase 1D (PTP1D) binding, PTP1D phosphorylation, PTP1D complex formation with Grb2-Son of sevenless 1 (Sos1), and Sos1 phosphorylation. gp130 phosphorylation, gp130-to-PTP1D binding, PTP1D phosphorylation, and PTP1D-to-Grb2 binding are also induced by IL-6 in all IL-6-independent MM cell lines studied. However, Grb2 is not associated with Sos1, and neither Grb2-to-Sos1 binding nor Sos1 phosphorylation is triggered by IL-6 in OCI-My5 MM cells. On the other hand, Grb2 and Sos1 are associated constitutively in U266 and RPMI8226 MM cells, but phosphorylation of Sos1 is not induced by IL-6. These data suggest that lack of Sos1 activation is associated with loss of IL-6 responsiveness in MM cell lines that grow independently of IL-6.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815779

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

1.  Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.

Authors:  Teru Hideshima; Laurence Catley; Hiroshi Yasui; Kenji Ishitsuka; Noopur Raje; Constantine Mitsiades; Klaus Podar; Nikhil C Munshi; Dharminder Chauhan; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

Review 2.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

3.  Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events.

Authors:  Leticia Quintanilla-Martinez; Marcus Kremer; Katja Specht; Julia Calzada-Wack; Michaela Nathrath; Robert Schaich; Heinz Höfler; Falko Fend
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

4.  The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.

Authors:  A Scuto; P Krejci; L Popplewell; J Wu; Y Wang; M Kujawski; C Kowolik; H Xin; L Chen; Y Wang; L Kretzner; H Yu; W R Wilcox; Y Yen; S Forman; R Jove
Journal:  Leukemia       Date:  2010-12-17       Impact factor: 11.528

5.  In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.

Authors:  Martin Schmidt-Hieber; Robert Dabrowski; Andreas Weimann; Babette Aicher; Philipp Lohneis; Antonia Busse; Eckhard Thiel; Igor W Blau
Journal:  Invest New Drugs       Date:  2010-11-16       Impact factor: 3.850

6.  Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.

Authors:  Makoto Hamasaki; Teru Hideshima; Pierfrancesco Tassone; Paola Neri; Kenji Ishitsuka; Hiroshi Yasui; Norihiko Shiraishi; Noopur Raje; Shaji Kumar; Donald H Picker; Gary S Jacob; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2005-02-10       Impact factor: 22.113

Review 7.  New frontiers in the treatment of multiple myeloma.

Authors:  Janice Jin Hwang; Irene M Ghobrial; Kenneth C Anderson
Journal:  ScientificWorldJournal       Date:  2006-12-06

Review 8.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

9.  Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.

Authors:  Sarah A Holstein; Huaxiang Tong; Raymond J Hohl
Journal:  Leuk Res       Date:  2009-07-30       Impact factor: 3.156

10.  SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.

Authors:  Yutaka Okawa; Teru Hideshima; Paul Steed; Sonia Vallet; Steven Hall; Ken Huang; John Rice; Amy Barabasz; Brianna Foley; Hiroshi Ikeda; Noopur Raje; Tanyel Kiziltepe; Hiroshi Yasui; Sotaro Enatsu; Kenneth C Anderson
Journal:  Blood       Date:  2008-10-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.